Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Biofuels feature algae header

In Depth 18 Mar 2019

The Search for a Better Biofuel: Can Biotech Deliver?

With dire climate change reports landing one after another in 2018 the need for sustainable, scalable, and affordable biofuels to aid in this transition to a more sustainable future has never been greater. Ticking all three boxes is no easy task, but the biotech sector has several promising solutions in development. Producing carbon-neutral fuels from […]

March 18, 2019 - 7 minutesmins - By Farhan Mitha

samsara anti aging apollo ventures 1

Startup Scout 15 Mar 2019

This Biotech Wants You to Age Well

Age is a risk factor in many diseases, such as cancer and heart disease. The UK biotech Samsara Therapeutics thinks that it can make drugs that can prevent multiple conditions at once by targeting the aging process itself. Mission: To develop drugs that target the biological mechanisms underlying aging. Slowing the aging process seems like […]

March 15, 2019 - 4 minutesmins - By Jonathan Smith

microsoft synthace oxford biomedica gene therapy cell therapy

News and Trends 14 Mar 2019

Microsoft Aims to Make Cell Therapies Cheaper with Artificial Intelligence

Microsoft has launched a collaboration with the UK company Oxford BioMedica to use Microsoft’s artificial intelligence technology to make gene and cell therapy manufacturing easier and cheaper. Genetically programming cells and viruses to make cell and gene therapies is not as simple as programming a computer. Organisms have many layers of complexity and unpredictability, sometimes […]

March 14, 2019 - 2 minutesmins - By Jonathan Smith

arthritis pediatric juvenile idiopathic Leuven

News and Trends 13 Mar 2019

Artificial Intelligence Detects Juvenile Arthritis in the Blood

Using artificial intelligence, a Belgian research group can diagnose juvenile arthritis from blood samples with almost 90% accuracy and identify different forms of the disease, something that is not currently possible. Juvenile idiopathic arthritis causes joint pain, swelling and stiffness in children under the age of 16. The disease is hard to treat because there […]

March 13, 2019 - 3 minutesmins - By Jonathan Smith

osteoarthritis stem cell regenerative medicine

News and Trends 12 Mar 2019

Stem Cells and Hydrogel Make Potential Osteoarthritis Treatment

Scientists from the Netherlands have received a €600,000 grant to test a treatment for osteoarthritis in humans that combines hydrogels and stem cells to help the knee joint heal. In osteoarthritis, the cartilage in joints such as the knees breaks down, causing stiffness and pain. There is no cure at the moment, and most current […]

March 12, 2019 - 3 minutesmins - By Jonathan Smith

geneuro multiple sclerosis neuron viral dna

News and Trends 12 Mar 2019

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

An antibody that blocks the action of a hidden viral protein encoded by our genome shows encouraging signs of slowing down the progression of multiple sclerosis, according to the Swiss biotech GeNeuro which carried out the research. GeNeuro’s monoclonal antibody drug targets the hidden viral protein because it’s linked to the occurrence of multiple sclerosis, […]

March 12, 2019 - 3 minutesmins - By Jonathan Smith

ADVERTISEMENT

SNIPR bio story Bacterial cell

News and Trends 11 Mar 2019

Danish Biotech to Develop CRISPR-Based Microbiome Treatments

SNIPR Biome has raised €43M in Series A funds to develop treatments that precisely target ‘bad’ bacteria using CRISPR gene editing, while keeping the rest of the patient’s microbiome intact. Founded with €2.6M seed investment from the Lundbeck Foundation in 2017, SNIPR Biome was the first exploratory investment for the Danish organisation’s Emerge fund, which […]

March 11, 2019 - 2 minutesmins - By Helen Albert

HIV treatment monthly injection

News and Trends 11 Mar 2019

Monthly Injection Proves as Good as Daily Pills Against HIV in Phase III

Two phase III trials conducted by ViiV Healthcare have concluded that a monthly injection of two anti-HIV drugs is as effective as the standard daily treatment taken by people infected with HIV. The results showed that, after 11 months, the monthly treatment achieved virus suppression levels of over 90% and similar to those of conventional […]

March 11, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

artificial pancreas type 1 diabetes

In Depth 11 Mar 2019

The Three Steps Needed to Fully Automate the Artificial Pancreas

New advances in diabetes research are making it possible to develop a fully automated insulin delivery system that can control blood sugar without any input from the patient. This so-called artificial pancreas could be here within the next decade, but there are still three main challenges that scientists have to address to get us there. […]

March 11, 2019 - 11 minutesmins - By Clara Rodríguez Fernández

Next generation sequencing Nick McCooke Solexa DNA electronics

Interview 11 Mar 2019

The Man Behind Next-Generation Sequencing

Nick McCooke shares the story behind the invention of next-generation sequencing at Solexa and his latest adventure in the sequencing world with the company DNA Electronics. Nick McCooke led the pioneer team at Solexa that invented next-generation sequencing, a technology to read DNA at high speed that is nowadays used worldwide and has laid the […]

March 11, 2019 - 9 minutesmins - By Clara Rodríguez Fernández

ulcerative colitis abivax hiv header

News and Trends 8 Mar 2019

HIV Drug Shows Promise for Treating Ulcerative Colitis Patients

A small molecule drug, developed by the company Abivax for treating HIV, has also shown promise for patients with the inflammatory bowel disease ulcerative colitis, reducing the disease severity consistently for over six months. Abivax tested the drug on patients with moderate-to-severe cases of ulcerative colitis, an inflammatory bowel condition that causes rectal bleeding and […]

March 8, 2019 - 3 minutesmins - By Jonathan Smith

influenza virus antiviral drugs atriva therapeutics germany tuebingen 1

News and Trends 8 Mar 2019

Flu Resistant to Antivirals? This Biotech Has a Drug for That

We are visiting the medieval German city of Tübingen this week. It hosts the biotech Atriva Therapeutics, which is developing antiviral drugs for influenza that can circumvent drug resistance. Mission: To make antiviral drugs that, unlike conventional drugs, target the host cell instead of the virus. This can prevent the virus from building resistance to […]

March 8, 2019 - 3 minutesmins - By Jonathan Smith

ADVERTISEMENT